243 related articles for article (PubMed ID: 25951372)
1. Targeted Therapies for Prostate Cancer.
Petrioli R; Francini E; Fiaschi AI; Laera L; Roviello G
Cancer Invest; 2015; 33(7):276-85. PubMed ID: 25951372
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in the treatment of castration-resistant prostate cancer.
Derleth CL; Yu EY
Oncology (Williston Park); 2013 Jul; 27(7):620-8. PubMed ID: 23977754
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
Priolo C; Oh WK; Loda M
IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
[TBL] [Abstract][Full Text] [Related]
4. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
5. Approaches to the treatment of patients with hormone-sensitive prostate cancer.
DiPaola RS
Semin Oncol; 1999 Oct; 26(5 Suppl 17):24-7. PubMed ID: 10604265
[TBL] [Abstract][Full Text] [Related]
6. Castration-resistant prostate cancer: targeted therapies.
Leo S; Accettura C; Lorusso V
Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
[TBL] [Abstract][Full Text] [Related]
7. New drugs for prostate cancer.
Alifrangis C; O'Hanlon-Brown C; Tuthill M; Waxman J
BJU Int; 2012 Jun; 109(12):1801-6. PubMed ID: 21933331
[TBL] [Abstract][Full Text] [Related]
8. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in prostate cancer.
Corcoran NM; Gleave ME
Histopathology; 2012 Jan; 60(1):216-31. PubMed ID: 22212088
[TBL] [Abstract][Full Text] [Related]
10. Targeting metastatic prostate cancer: the search for innovative systemic therapies.
Berthold DR; Moore MJ
Oncology (Williston Park); 2006 Dec; 20(14):1787-91; discussion 1791-6. PubMed ID: 17263128
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR; Wilson TR; Settleman J
Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
[TBL] [Abstract][Full Text] [Related]
13. New agents for prostate cancer.
Reese DM
Hematol Oncol Clin North Am; 2001 Jun; 15(3):547-57. PubMed ID: 11525296
[TBL] [Abstract][Full Text] [Related]
14. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
15. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Saad F; Miller K
Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
[TBL] [Abstract][Full Text] [Related]
16. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
17. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
18. Personalizing prostate cancer therapy: the way forward.
Cetnar JP; Beer TM
Drug Discov Today; 2014 Sep; 19(9):1483-7. PubMed ID: 25046532
[TBL] [Abstract][Full Text] [Related]
19. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
Clarke NW
BJU Int; 2012 Oct; 110 Suppl 1():14-22. PubMed ID: 23046036
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
Bhandari MS; Petrylak DP; Hussain M
Eur J Cancer; 2005 Apr; 41(6):941-53. PubMed ID: 15808960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
